• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Orexigen Therapeutics, Inc. (OREX)

    1.84 Down 0.05(2.65%) Feb 5, 4:00PM EST
    |After Hours : 1.94 Up 0.10 (5.43%) Feb 5, 6:59PM EST
    ProfileGet Profile for:
    Orexigen Therapeutics, Inc.
    3344 North Torrey Pines Court
    Suite 200
    La Jolla, CA 92037
    United States - Map
    Phone: 858-875-8600
    Fax: 858-875-8650
    Website: http://www.orexigen.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:47

    Business Summary 

    Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Orexigen Therapeutics, Inc.

    Corporate Governance 
    Orexigen Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Michael A. Narachi M.S., M.B.A., 57
    Chief Exec. Officer, Pres, Interim Chief Financial Officer and Director
    Dr. Preston S. Klassen M.D., M.H.S., 47
    Head of Global Devel. and Exec. VP
    Mr. Joseph P. Hagan , 47
    Mr. Mark D. Booth , 56
    Stephen Moglia ,
    Principal Accounting Officer and Controller
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders